Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia.

Christie JE, Shering A, Ferguson J, Glen AI.

Br J Psychiatry. 1981 Jan;138:46-50.

PMID:
7023592
2.

Multiple-dose arecoline infusions in Alzheimer's disease.

Tariot PN, Cohen RM, Welkowitz JA, Sunderland T, Newhouse PA, Murphy DL, Weingartner H.

Arch Gen Psychiatry. 1988 Oct;45(10):901-5.

PMID:
3048224
3.
4.

Effects of long-term continuous infusion of the muscarinic cholinergic agonist arecoline on verbal memory in dementia of the Alzheimer type.

Raffaele KC, Berardi A, Asthana S, Morris P, Haxby JV, Soncrant TT.

Psychopharmacol Bull. 1991;27(3):315-9.

PMID:
1775605
5.
6.

Physostigmine effects in Alzheimer's disease: relationship to dementia severity.

Schwartz AS, Kohlstaedt EV.

Life Sci. 1986 Mar 17;38(11):1021-8.

PMID:
3512944
7.

Treatment of Alzheimer disease by continuous intravenous infusion of physostigmine.

Asthana S, Raffaele KC, Berardi A, Greig NH, Haxby JV, Schapiro MB, Soncrant TT.

Alzheimer Dis Assoc Disord. 1995 Winter;9(4):223-32.

PMID:
8749612
8.
9.

Oral physostigmine and lecithin improve memory in Alzheimer disease.

Thal LJ, Fuld PA, Masur DM, Sharpless NS.

Ann Neurol. 1983 May;13(5):491-6.

PMID:
6347034
10.

Effects of physostigmine and lecithin on memory in Alzheimer disease.

Peters BH, Levin HS.

Ann Neurol. 1979 Sep;6(3):219-21.

PMID:
534419
11.

Effects of acute infusion of the muscarinic cholinergic agonist arecoline on verbal memory and visuo-spatial function in dementia of the Alzheimer type.

Raffaele KC, Berardi A, Morris PP, Asthana S, Haxby JV, Schapiro MB, Rapoport SI, Soncrant TT.

Prog Neuropsychopharmacol Biol Psychiatry. 1991;15(5):643-8.

PMID:
1956992
12.

Effects of oral physostigmine in Alzheimer's disease.

Stern Y, Sano M, Mayeux R.

Ann Neurol. 1987 Sep;22(3):306-10.

PMID:
3674795
13.
14.

Safety and efficacy of oral physostigmine in the treatment of Alzheimer disease.

Sano M, Bell K, Marder K, Stricks L, Stern Y, Mayeux R.

Clin Neuropharmacol. 1993 Feb;16(1):61-9.

PMID:
8422658
15.
16.

Neuroendocrine responses to intravenous infusion of physostigmine in patients with Alzheimer disease.

Asthana S, Raffaele KC, Greig NH, Schapiro MB, Blackman MR, Soncrant TT.

Alzheimer Dis Assoc Disord. 1999 Apr-Jun;13(2):102-8.

PMID:
10372954
17.

Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease.

Asthana S, Greig NH, Holloway HW, Raffaele KC, Berardi A, Schapiro MB, Rapoport SI, Soncrant TT.

Clin Pharmacol Ther. 1996 Sep;60(3):276-82.

PMID:
8841150
18.

Memory enhancement with oral physostigmine in Alzheimer's disease.

[No authors listed]

N Engl J Med. 1983 Mar 24;308(12):720-1. No abstract available.

PMID:
6338388
19.

Improved verbal learning after outpatient oral physostigmine therapy in patients with dementia of the Alzheimer type.

Sevush S, Guterman A, Villalon AV.

J Clin Psychiatry. 1991 Jul;52(7):300-3.

PMID:
2071560
20.

Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease.

Thal LJ, Masur DM, Blau AD, Fuld PA, Klauber MR.

J Am Geriatr Soc. 1989 Jan;37(1):42-8. Review.

PMID:
2642499

Supplemental Content

Support Center